Abstract
ABSTRACTObjective:To gather information on penile cancer epidemiologic trends and its economic impact on the Brazilian Public Health System across the last 25 years.Methods:The Brazilian Public Health System database was used as the primary source of data from January 1992 to December 2017. Mortality and incidence data from the Instituto Nacional de Câncer José Alencar Gomes da Silva was collected using the International Classification of Diseases ICD10 C60. Demographic data from the Brazilian population was obtained from the last census by the Brazilian Institute of Geography and Statistics, performed in 2010 and its 2017 review.Results:There were 9,743 hospital admissions related to penile cancer from 1992 to 2017. There was a reduction (36%) in the absolute number of admissions per year related to penile cancer in 2017, as compared to 1992 (2.7versus 1.7 per 100,000; p<0.001). The expenses with admissions related to this condition in this period were US$ 3,002,705.73 (US$ 115,488.68/year). Approximately 38% of the total amount was spent in Northeast Region. In 1992, penile cancer costed US$ 193,502.05 to the public health system, while in 2017, it reduced to US$ 47,078.66 (p<0.02). Penile cancer incidence in 2017 was 0.43/100,000 male Brazilian, with the highest incidence rate found in the Northeast Region. From 1992 to 2017, the mortality rates of penile cancer in Brazil were 0.38/100,000 man, and 0.50/100,000 man in the North Region.Conclusion:Despite the decrease in admissions, penile cancer still imposes a significant economic and social burden to the Brazilian population and the Public Health System.
Highlights
Penile cancer (PC) is a rare disease, accounting for 0.4% to 0.6% of all malignant neoplasms among men in the United States and Europe.[1,2] it is well documented that the incidence of PC is higher in developing countries, and may account for as high as 10% to 20% of male urogenital tumors in these regions.[3,4] relatively rare, PC has a 5-year survival rate of approximately 50%, and many times results in devastating disfigurement.[5]In general, PC presents as a palpable, visible and painless lesion on the penis
Descritores: Neoplasias penianas; Custos e análise de custo; Carcinoma de células escamosas; Indicadores de desenvolvimento; Saúde pública; Sistema Único de Saúde In Brazil, PC may account for 2.1% of all neoplasms in men and affects mainly inhabitants of the North and Northeast Regions,(15,16) two geographic areas historically marked by great social inequality and extreme poverty
The Brazilian Public Health System Database (DATASUS – Departamento de Informática do Sistema Único de Saúde Brasil) represents the main effort of the Federal Government to collect data from the SUS, and it was used as the primary source of data for our study, along with the Hospital Information System (SIH – Sistema de Informações Hospitalares/Sistema Único de Saúde) from SUS.[18]. Epidemiologic data were analyzed from January 1992 to December 2017, gathering information on admissions to public hospitals registered under the following codes: penis amputation, oncology penis amputation, and extended total penile amputation
Summary
Penile cancer (PC) is a rare disease, accounting for 0.4% to 0.6% of all malignant neoplasms among men in the United States and Europe.[1,2] it is well documented that the incidence of PC is higher in developing countries, and may account for as high as 10% to 20% of male urogenital tumors in these regions.[3,4] relatively rare, PC has a 5-year survival rate of approximately 50% (over 85% for patients with negative lymph nodes, and 29% and 40% with positive nodes), and many times results in devastating disfigurement.[5]In general, PC presents as a palpable, visible and painless lesion on the penis. A population-based study, conducted in Sweden, reported an increased risk of invasive PC among individuals with lower income and level of education. This is probably related to some factors, such as delay in seeking care, disease stigma, fear of treatment, and lack of knowledge about the diagnosis.[13,14]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
